Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease?

Current Alzheimer Research

Volumn 7, Issue 6, 2010, Pages 506-516

  Fitzgerald, P J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta blocker; Bipolar disorder; Clonidine; Dementia; Desipramine; Guanfacine; Hypertension; Obesity; Propranolol; Psychological stress; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DESIPRAMINE; DONEPEZIL; FLUOXETINE; IDAZOXAN; IMIPRAMINE; NORADRENALIN; NORTRIPTYLINE; PHYSOSTIGMINE; PROPRANOLOL; SEROTONIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BIPOLAR DISORDER; BIPOLAR II DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DEPRESSION; ELECTROENCEPHALOGRAM; HUMAN; HYPERTENSION; LIGAND BINDING; MENTAL STRESS; MINI MENTAL STATE EXAMINATION; NONHUMAN; NORADRENERGIC SYSTEM; OBESITY; PRIORITY JOURNAL; VERBAL HOSTILITY; WORKING MEMORY;

ADRENERGIC AGENTS; ALZHEIMER DISEASE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; HUMANS; MENTAL DISORDERS; MODELS, BIOLOGICAL; NOREPINEPHRINE;

EID: 78549246749     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510792231775     Document Type: Article

References (133)

1. Meyer JS, Quenzer LF. Psychopharmacology: drugs, the brain, and behavior; Sinauer Associates, Inc., Sunderland, Massachusetts 136: 132-133 (2005).
2. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 5: 342-5 (2008).
3. Johannsen P. Long-term cholinesterase inhibitor treatment of Alzheimer's disease. CNS Drugs 18: 757-68 (2004).
4. Alexopoulos GS. The treatment of depressed demented patients. J Clin Psychiatry 57 Suppl 14: 14-20 (1996).
5. Raskind MA, Peskind ER, Holmes C, Goldstein DS. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease. Biol Psychiatry 46: 756-65 (1999).
6. Elrod R, Peskind ER, DiGiacomo L, Brodkin KI, Veith RC, Raskind MA. Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 154: 25-30 (1997).
7. Raskind MA, Peskind ER, Halter JB, Jimerson DC. Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease. Arch Gen Psychiatry 41: 343-6 (1984).
8. Lawlor BA, Bierer LM, Ryan TM, Schmeidler J, Knott PJ, Williams LL, et al. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol Psychiatry 38: 185-8 (1995).
9. Peskind ER, Wingerson D, Murray S, Pascualy M, Dobie DJ, Le Corre P, et al. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 52: 774-82 (1995).
10. D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 22: 229-36 (1987).
11. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 401: 231-8 (1987a).
12. Palmer AM, Francis PT, Bowen DM, Benton JS, Neary D, Mann DM, et al. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res 414: 365-75 (1987b).
13. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) 288: 961-4 (1984).
14. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1: 256-62 (1987a).
15. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP. Age and histopathologic heterogeneity in Alzheimer's disease. Evidence for subtypes. Arch Gen Psychiatry 44: 412-7 (1987b).
16. Tejani-Butt SM, Yang J, Zaffar H. Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Res 631: 147-50 (1993).
17. He M, Sibille E, Benjamin D, Toth M, Shippenberg T. Differential effects of 5-HT1A receptor deletion upon basal and fluoxetineevoked 5-HT concentrations as revealed by in vivo microdialysis. Brain Res 902: 11-7 (2001).
18. Heils A, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (Ecstasy) in serotonin transporter-deficient mice. Mol Pharmacol 53: 649-55 (1998).
19. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 26: 467-78 (2006).
20. Szot P, Leverenz JB, Peskind ER, Kiyasu E, Rohde K, Miller MA, et al. Tyrosine hydroxylase and norepinephrine transporter mRNA expression in the locus coeruleus in Alzheimer's disease. Brain Res Mol Brain Res 84: 135-40 (2000).
21. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Bio-chemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem 47: 1295-301 (1986).
22. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 146: 471-80 (2007).
23. Sharp SI, Ballard CG, Chen CP, Francis PT. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatr Psychiatry 15: 435-7 (2007).
24. Sara SJ. Noradrenergic-cholinergic interaction: its possible role in memory dysfunction associated with senile dementia. Arch Gerontol Geriatr Suppl 1: 99-108 (1989).
25. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 59: 5-12 (2004).
26. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18: 294-297 (1994).
27. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38: 246-52 (1997).
28. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8: 270-5 (1996).
29. Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol 42: 894-6 (1985).
30. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 15: 15-28 (1999).
31. Bartlome P, King KS, Matsuo F, Wood JS. Cognitive decline with nortriptyline use in a patient with dementia of the Alzheimer's type. West J Med 156: 75-7 (1992).
32. Reifler BV, Teri L, Raskind M, Veith R, Barnes R and White E, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 146: 45-9 (1989).
33. Moskowitz H, Burns MM. Cognitive performance in geriatric subjects after acute treatment with antidepressants. Neuropsychobiology 15 Suppl 1: 38-43 (1986).
34. Mattila M, Mattila MJ, Vrijmoed-de Vries M, Kuitunen T. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 65: 81-8 (1989).
35. Egashira N, Iwasaki K, Takashima A, Watanabe T, Kawabe H, Matsuda T, et al. Altered depression-related behavior and neuro-chemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. Brain Res 1059: 7-12 (2005).
36. Pakaski M, Bjelik A, Hugyecz M, Kasa P, Janka Z, Kalman J. Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int 47: 190-5 (2005).
37. Golan DE, Tashjian Jr. AH, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy; Lippincott Williams & Wilkins, Baltimore, Maryland, p.110 (2005).
38. Riekkinen P Jr., Riekkinen M. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. Neuropsychopharmacology 20: 357-64 (1999).
39. Riekkinen M, Laakso MP, Jakala P. Clonidine impairs sustained attention and memory in Alzheimer's disease. Neuroscience 92: 975-82 (1999).
40. Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, et al. Clonidine treatment of Alzheimer's disease. Arch Neurol 46: 376-8 (1989).
41. Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia 5: 243-6 (1994).
42. Crook T, Wilner E, Rothwell A, Winterling D, McEntee W. Noradrenergic intervention in Alzheimer's disease. Psychopharmacol Bull 28: 67-70 (1992).
43. Herrmann N, Lanctot KL, Eryavec G, Van Reekum R, Khan LR. Growth hormone response to clonidine predicts aggression in Alzheimer's disease. Psychoneuroendocrinology 29: 1192-7 (2004).
44. Goodwin GM, Conway SC, Peyro-Saint-Paul H, Glabus MF, O'Carroll RE, Ebmeier KP. Executive function and uptake of 99mTc-exametazime shown by single photon emission tomography after oral idazoxan in probable Alzheimer-type dementia. Psychopharmacol (Berl) 131: 371-8 (1997).
45. Coull JT, Sahakian BJ, Hodges JR. The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacol (Berl) 123: 239-49 (1996).
46. Arnsten AF, Contant TA. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacol (Berl) 108: 59-69 (1992).
47. Weiler PG, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1: 226-30 (1988).
48. Shankle WR, Nielson KA, Cotman CW. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 9: 233-7 (1995).
49. Herrmann N, Lanctot KL, Eryavec G, Khan LR. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. J Psychopharmacol 18: 215-20 (2004).
50. Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 19: 23-8 (2005).
51. Gliebus G, Lippa CF. The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am J Alzheimers Dis Other Demen 22: 57-61 (2007).
52. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in beta-adrenergic receptor subtypes in Alzheimer-type dementia. J Neurochem 48: 1215-21 (1987).
53. Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR. Adrenergic receptors in aging and Alzheimer's disease: increased beta 2-receptors in prefrontal cortex and hippocampus. J Neurochem 53: 1772-81 (1989).
54. Saber AJ, Cain DP. Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. Neuropsychopharmacology 28: 1247-56 (2003).
55. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509-522 (1965).
56. Jimerson DC, Nurnberger Jr. JI, Post RM, Gershon ES, Kopin IJ. Plasma MHPG in rapid cyclers and healthy twins. Arch Gen Psychiatry 38: 1287-1290 (1981).
57. Burdick KE, Funke B, Goldberg JF, Bates JA, Jaeger J, Kucherlapati R, Malhotra AK. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 9: 370-6 (2007).
58. rd, Hoblyn JC, Kraemer HC, Yesavage JA. Factors associated with psychiatric hospitalization of individuals diagnosed with dementia and comorbid bipolar disorder. J Geriatr Psychiatry Neurol 19: 72-7 (2006).
59. Dorey JM, Beauchet O, Thomas Anterion C, Rouch I, Krolak-Salmon P, Gaucher J, et al. Behavioral and psychological symptoms of dementia and bipolar spectrum disorders: review of the evidence of a relationship and treatment implications. CNS Spectr 13: 796-803 (2008).
60. Ng B, Camacho A, Lara DR, Brunstein MG, Pinto OC, Akiskal HS. A case series on the hypothesized connection between dementia and bipolar spectrum disorders: bipolar type VI? J Affect Disord 107: 307-15 (2008).
61. Sajatovic M, Blow FC, Ignacio RV. Psychiatric comorbidity in older adults with bipolar disorder. Int J Geriatr Psychiatry 21: 582-7 (2006).
62. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood. Br J Psychiatry 157: 81-6, 92-4 (1990).
63. Lyketsos CG, Corazzini K, Steele C. Mania in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 7: 350-2 (1995).
64. Fahim S, van Duijn CM, Baker FM, Launer L, Breteler MM, Schudel WJ, et al. A study of familial aggregation of depression, dementia and Parkinson's disease. Eur J Epidemiol 14: 233-8 (1998).
65. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30: 1125-8 (2006).
66. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 190: 359-60 (2007).
67. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 65: 1331-5 (2008).
68. Kelly T. Is donepezil useful for improving cognitive dysfunction in bipolar disorder? J Affect Disord 107: 237-40 (2008).
69. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205: 2781-9 (2008).
70. Solt VB, Brown MR, Kennedy B, Kolterman OG, Ziegler MG. Elevated insulin, norepinephrine, and neuropeptide Y in hypertension. Am J Hypertens 3: 823-828 (1990).
71. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 9: 399-405 (2007).
72. Eide I, Kolloch R, DeQuattro V, Miano L, Dugger R, Van der Meulen J. Raised cerebrospinal fluid norepinephrine in some patients with primary hypertension. Hypertension 1: 255-60 (1979).
73. DeQuattro V, Sullivan P, Minagawa R, Kopin I, Bornheimer J, Foti A, et al. Central and peripheral noradrenergic tone in primary hypertension. Fed Proc 43: 47-51 (1984).
74. Kawano Y, Fukiyama K, Takeya Y, Abe I, Omae T. Catecholamines, angiotensin II and sodium concentrations in cerebrospinal fluid in young men with borderline hypertension. Clin Exp Hypertens A 6: 1131-45 (1984).
75. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 28: 605-11 (2006).
76. Thorpe J, Widman LP, Wallin A, Beiswanger J, Blumenthal HT. Comorbidity of other chronic age-dependent diseases in dementia. Aging (Milano) 6: 159-66 (1994).
77. Sanderson M, Wang J, Davis DR, Lane MJ, Cornman CB, Fadden MK. Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen 17: 73-8 (2002).
78. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano) 13: 143-62 (2001).
79. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545-51 (2005).
80. Foroughan M, Farahani ZG, Shariatpanahi M, Vaezinejad M, Kamerani AA, Sheikhvatan M. Risk factors of Alzheimer's disease among Iranian population. Curr Alzheimer Res 5: 70-2 (2008).
81. Bhargava D, Weiner MF, Hynan LS, Diaz-Arrastia R, Lipton AM. Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease. J Geriatr Psychiatry Neurol 19: 78-82 (2006).
82. Reitz C, Patel B, Tang MX, Manly J, Mayeux R, Luchsinger JA. Relation between vascular risk factors and neuropsychological test performance among elderly persons with Alzheimer's disease. J Neurol Sci 257: 194-201 (2007).
83. Black SE, Patterson C, Feightner J. Preventing dementia. Can J Neurol Sci 28 Suppl 1: S56-66 (2001).
84. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163: 1069-75 (2003).
85. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7: 683-9 (2008).
86. Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1850-8 (2007).
87. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 111: 3429-3434 (2005).
88. Oltmans GA, Lorden JF, Margules DL. Effects of food restriction and mutation on central catecholamine levels in genetically obese mice. Pharmacol Biochem Behav 5: 617-20 (1976).
89. Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob). Brain Res 273: 369-73 (1983).
90. Shimazu T, Noma M, Saito M. Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res 369: 215-23 (1986).
91. Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev 9: 204-18 (2008).
92. Chiang CJ, Yip PK, Wu SC, Lu CS, Liou CW, Liu HC, et al. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am J Geriatr Psychiatry 15: 762-71 (2007).
93. Razay G, Vreugdenhil A, Wilcock G. Obesity, abdominal obesity and Alzheimer disease. Dement Geriatr Cogn Disord 22: 173-6 (2006).
94. Donini LM, De Felice MR, Cannella C. Nutritional status determinants and cognition in the elderly. Arch Gerontol Geriatr 44 (Suppl 1): 143-53 (2007).
95. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 4: 103-9 (2007).
96. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62: 1556-60 (2005).
97. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18- year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163: 1524-8 (2003).
98. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 48: 57-61 (2007).
99. Haan MN. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2: 159-66 (2006).
100. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26 Suppl 1: 65-9 (2005).
101. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4: 147-52 (2007).
102. Luchsinger JA, Mayeux R. Adiposity and Alzheimer's disease. Curr Alzheimer Res 4: 127-34 (2007).
103. Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis 15: 29-44 (2008).
104. Mrak RE. Alzheimer-type neuropathological changes in morbidly obese elderly individuals. Clin Neuropathol 28: 40-5 (2009).
105. Pardon MC, Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neurosci Biobehav Rev 32: 1103-20 (2008).
106. Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology 68: 2085-92 (2007).
107. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother 51: 367-75 (1997).
108. Wilson RS, Arnold SE, Schneider JA, Li Y, Bennett DA. Chronic distress, age-related neuropathology, and late-life dementia. Psychosom Med 69: 47-53 (2007).
109. Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology 61: 1479-85 (2003).
110. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology 27: 143-53 (2006).
111. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 3: 343-53 (2004).
112. Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, et al. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J 20: 729-31 (2006).
113. Feng Q, Cheng B, Yang R, Sun FY, Zhu CQ. Dynamic changes of phosphorylated tau in mouse hippocampus after cold water stress. Neurosci Lett 388: 13-6 (2005).
114. Hardebo JE, Owman C. Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Ann Neurol 8: 1-31 (1980).
115. Kutluhan S, Kilbas S, Demirci S, Cekic O, Bardak Y, Akhan G. Pheochromocytoma presenting with bithalamic infarction, dementia, and increased intraocular pressure. Ophthalmic Surg Lasers Imaging 38: 245-7 (2007).
116. White PD, Lishman WA, Wyke MA. Phaeochromocytoma as a cause of reversible dementia. J Neurol Neurosurg Psychiatry 49: 1449-51 (1986).
117. Guerin D, Sacquet J, Mandairon N, Jourdan F, Didier A. Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol Aging 30: 272-83 (2009).
118. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, et al. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28: 1206-14 (2007).
119. German DC, Nelson O, Liang F, Liang CL, Games D. The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J Comp Neurol 492: 469-76 (2005).
120. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26: 1343-54 (2006).
121. Shimizu Y, Tanishita T, Minokoshi Y, Shimazu T. Activation of mitogen-activated protein kinase by norepinephrine in brown adipocytes from rats. Endocrinology 138: 248-53 (1997).
122. Yamazaki T, Komuro I, Zou Y, Kudoh S, Shiojima I, Hiroi Y, et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation 95: 1260-8 (1997).
123. Sawada T, Ohmichi M, Koike K, Kanda Y, Kimura A, Masuhara K, et al. Norepinephrine stimulates mitogen-activated protein kinase activity in GT1-1 gonadotropin-releasing hormone neuronal cell lines. Endocrinology 138: 5275-81 (1997).
124. Klafki HW, Lewczuk P, Kamrowski-Kruck H, Maler JM, Muller K, Peters O, et al. Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. J Alzheimers Dis 18: 613-22 (2009).
125. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11: 144-58 (2001).
126. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, Linford NJ, et al. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 1772: 467-72 (2007).
127. Shimohama S, Kamiya S, Taniguchi T, Sumida Y, Fujimoto S. Differential involvement of small G proteins in Alzheimer's disease. Int J Mol Med 3: 597-600 (1999).
128. Maillet M, Robert SJ, Cacquevel M, Gastineau M, Vivien D, Bertoglio J, et al. Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat Cell Biol 5: 633-9 (2003).
129. Mei M, Su B, Harrison K, Chao M, Siedlak SL, Previll LA, et al. Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. J Neurochem 99: 1377-88 (2006).
130. Arendt T, Holzer M, Stobe A, Gartner U, Luth HJ, Bruckner MK, et al. Activated mitogenic signaling induces a process of dedifferentiation in Alzheimer's disease that eventually results in cell death. Ann N Y Acad Sci 920: 249-55 (2000).
131. Gartner U, Holzer M, Arendt T. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 91: 1-5 (1999).
132. Gartner U, Holzer M, Heumann R, Arendt T. Induction of p21ras in Alzheimer pathology. Neuroreport 6: 1441-4 (1995).
133. Greenberg SM, Koo EH, Selkoe DJ, Qiu WQ, Kosik KS. Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci USA 91: 7104-8 (1994).